At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 152 enrolled
Drug / intervention
BMS-790052 (NS5A Replication Complex Inhibitor) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Evaluation of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 4
In Brief
A Phase 3 clinical trial evaluating BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, and 2 other interventions for Hepatitis C. Completed, enrolled 152 participants across 26 sites in 7 countries.
Detailed Summary
The purpose of this study is to compare the sustained virologic response at post treatment Week 12 for each cohort (BMS-790052/Pegylated-interferon alfa 2a (pegIFNα-2a)/Ribavirin (RBV) versus placebo/PegIFNα-2a/RBV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesFrance, Greece, Italy, Puerto Rico, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartDec 2011
Primary CompletionOct 2013
Study CompletionJan 2014
TodayJul 2026
First PostedOct 7, 2011
Enrollment StartDec 1, 2011
Primary CompletionOct 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.7 years ago
Interventions
BMS-790052 (NS5A Replication Complex Inhibitor)drug
Placebo matching BMS-790052drug
Pegylated-interferon alfa 2adrug
Ribavirindrug